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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related haloge-
nated aromatic hydrocarbons (HAHs) are highly toxic to most
vertebrate animals, but there are dramatic differences in sensitivity
among species and strains. Aquatic birds including the common
tern (Sterna hirundo) are highly exposed to HAHs in the environ-
ment, but are up to 250-fold less sensitive to these compounds than
the typical avian model, the domestic chicken (Gallus gallus). The
mechanism of HAH toxicity involves altered gene expression sub-
sequent to activation of the aryl hydrocarbon receptor (AHR), a
basic helix–loop–helix-PAS transcription factor. AHR polymor-
phisms underlie mouse strain differences in sensitivity to HAHs and
polynuclear aromatic hydrocarbons, but the role of the AHR in
species differences in HAH sensitivity is not well understood. Here,
we show that although chicken and tern AHRs both exhibit specific
binding of [3H]TCDD, the tern AHR has a lower binding affinity and
exhibits a reduced ability to support TCDD-dependent transacti-
vation as compared to AHRs from chicken or mouse. We further
show through use of chimeric AHR proteins and site-directed
mutagenesis that the difference between the chicken and tern
AHRs resides in the ligand-binding domain and that two amino
acids (Val-325 and Ala-381) are responsible for the reduced activity
of the tern AHR. Other avian species with reduced sensitivity to
HAHs also possess these residues. These studies provide a molec-
ular understanding of species differences in sensitivity to dioxin-
like compounds and suggest an approach to using the AHR as a
marker of dioxin susceptibility in wildlife.
basic helix–loop–helix-PAS  comparative toxicology  mechanisms 
risk assessment  susceptibility
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) and structurallyrelated halogenated aromatic hydrocarbons (HAHs) and
polynuclear aromatic hydrocarbons (PAHs) cause altered gene
expression and toxicity through activation of the aryl hydrocar-
bon receptor (AHR), a ligand-dependent transcription factor
and member of the basic helix–loop–helix (bHLH)-PAS gene
family (1, 2). The functional properties of AHRs are broadly
conserved among vertebrate species; AHRs in fish, birds, and
mammals exhibit high-affinity binding of planar HAHs and
PAHs, associate with AHR nuclear translocator (ARNT), and
regulate the expression of CYP1A1 and other genes (3, 4).
Targeted disruption of the AHR in mice and fish embryos
prevents induction of CYP1A1 andmost forms of TCDD toxicity
(5–8).
Despite the general conservation of the vertebrate AHR
signaling pathway, there are large species and strain differ-
ences in sensitivity to TCDD (9, 10). Mouse strain differences
in sensitivity to TCDD are caused by differences in the
ligand-binding affinity of their polymorphic AHR variants
(11). Similar studies have implicated the AHR in differential
sensitivity to TCDD among strains of rats (12). Despite these
findings and previous research on species differences in prop-
erties of the AHR (13–16), the mechanisms responsible for
differential HAH sensitivity, including the role of the AHR,
remain poorly understood.
Some of the most dramatic differences in sensitivity to HAHs
occur in birds. The domestic chicken (Gallus gallus), an impor-
tant animal model for studying AHR signaling (17–19), is
extremely sensitive to the effects of TCDD and other HAHs,
including CYP1A induction, edema, hepatotoxicity, teratoge-
nicity, and embryolethality, effects that are known to be AHR-
dependent in other species (5–8). In contrast, several other avian
species are 10- to 1,000-fold less sensitive than chickens to these
effects (20–24). Although early biochemical studies suggested
that differences in AHR properties may contribute to this
differential sensitivity (25, 26), the exact role of the AHR
remains unclear. Understanding the mechanisms by which avian
species differ in their sensitivity to dioxin-like compounds is
important for risk assessment, particularly for species of fish-
eating birds that are highly exposed to these compounds in the
wild (27).
To obtain a molecular understanding of avian AHRs and their
role in differential sensitivity to HAHs, we cloned and se-
quenced AHR cDNAs from chicken and from common tern
(Sterna hirundo), an aquatic species that is 80- to 250-fold less
sensitive than chickens to effects of HAHs (23, 24, 28). After
demonstrating species-specific differences in TCDD-binding
affinity and other properties of chicken and tern AHRs, we
constructed chimeric receptors and used site-directed mutagen-
esis to identify two amino acid residues in the ligand-binding
domain (LBD) that account for the differences in AHR function,
and thus contribute to the species differences in sensitivity to
HAHs.
Results
Chicken and Tern AHRs Share High Sequence Identity and Exhibit
Specific Binding of TCDD. We obtained full-length cDNA se-
quences for chicken and tern AHRs, which encode proteins of
858 aa (96.2 kDa) and 859 aa (96.3 kDa), respectively. The
chicken AHR cDNA sequence matches that reported recently
(29). The amino acid sequences of the chicken and tern AHRs
are highly similar, with 92% identity overall (Fig. 5, which is
published as supporting information on the PNAS web site).
They share especially high sequence identity (98%) in the region
encompassing amino acids 235–402 of the chicken AHR (tern
amino acids 236–403), which corresponds to the LBD (amino
acids 230–397) of the mouse AHR (30). The chicken and tern
AHRs both belong to the AHR1 clade (4), and thus are orthologs
of the human AHR.
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Full-length chicken and tern AHR proteins synthesized by in
vitro transcription and translation (IVTT) were expressed at
similar levels (Fig. 1A). The ability of the in vitro-expressed
chicken and tern AHRs to bind [3H]TCDDwas assessed by using
a velocity sedimentation (VS) assay (31) that has proven valu-
able in characterizing IVTT-expressed AHRs from a variety of
species (32–35). Chicken and tern AHRs both exhibited specific
binding of [3H]TCDD (2 nM) (Fig. 1B), but specific binding by
the tern AHR was only 25% of that measured with the chicken
AHR, even at a high concentration of [3H]TCDD (10 nM) (Fig.
1C). Varying the incubation time between 2 and 18 h had no
effect on the amount of specific binding (Fig. 6, which is
published as supporting information on the PNAS web site).
Thus, the chicken and tern AHRs differ in their ability to bind
[3H]TCDD.
Chicken and Tern AHRs Differ in TCDD-Binding Affinities and Trans-
activation Potential. To compare the TCDD-binding affinities of
the chicken and tern AHRs, we first performed saturation
binding analysis on in vitro synthesized AHR proteins using
[3H]TCDD and the hydroxylapatite (HAP) adsorption assay
(36). The mouse AHR (2) was used as a positive control. Both
the mouse and chicken AHRs exhibited high-affinity specific
binding, with KD values of 2.39  0.80 and 1.49  0.78 nM,
respectively (Fig. 2A). In contrast, specific binding of [3H]TCDD
by the tern AHRwas undetectable (1 fmol, compared to 124
8 fmol for mouse AHR and 56 23 fmol for chicken AHR) (Fig.
Fig. 1. [3H]TCDD binding by in vitro-expressed chicken, tern, and mouse
AHRs. (A) IVTT of AHRs. AHR constructs pSPORTMAHR (M), pcDNA-GgAHR (C),
and pcDNA-ShAHR (T) were expressed in the presence of [35S]methionine. (B
andC) AHRs were incubated overnight at 4°C with [3H]TCDD (B, 2 nM;C, 10 nM
final concentration) and then analyzed by VS. The binding of [3H]TCDD to UPL
measures NSB. Specific binding  total binding (radioligand binding to
AHR)  NSB (radioligand binding to UPL).
Fig. 2. [3H]TCDD saturation binding and transactivation by chicken, tern, and
mouse AHRs. (A) Saturation binding assessed by HAP assay. AHRs were expressed
by IVTT, incubatedwithvarious concentrationsof [3H]TCDDovernightat4°C,and
analyzed by the HAP assay (standard or filtered) as described in Materials and
Methods. Specificbindingwascalculatedasthedifferencebetweentotalbinding
and NSB. Only the specific binding curves are shown. Equilibrium dissociation
constants (KD) were calculated by nonlinear regression. Results shown are rep-
resentative of two to four independent experiments. Mean values (SD) for KD
andBmax were 2.390.80 nM and 1248 fmol per tube (mouse AHR,n3) and
1.49 0.78 nM and 56 23 fmol per tube (chicken AHR, n 4). Specific binding
of [3H]TCDD by the tern AHR was undetectable (1 fmol per tube). (B) Saturation
binding assessed by VS assay. AHRs were expressed by IVTT, incubated with
[3H]TCDD overnight at 4°C, and analyzed by VS. Specific binding (shown) was
calculated as the difference between total binding and NSB (Fig. 7). (C) Transac-
tivation of an AHRE-driven luciferase reporter gene by chicken, tern, and mouse
AHRs. COS-7 cells were transfected with pGudLuc 6.1, pcDNA-ARNT2, and pRL-
TK, along with expression constructs for chicken, tern, or mouse AHR. Cells were
treated with DMSO or TCDD (0–10 nM), and luciferase activities were measured.
Data are mean SD of triplicate determinations.















2A). This result suggests that the tern AHR-TCDD complex may
be sensitive to the washes used to remove nonspecifically bound
[3H]TCDD from HAP, as found for the human AHR (34, 37).
Therefore, we performed saturation binding analysis using the
gentler VS assay. Both chicken and tern AHRs exhibited satu-
rable specific binding to [3H]TCDD (Fig. 7, which is published
as supporting information on the PNAS web site), withKD values
of 0.52 nM (chicken) and 3.73 nM (tern), reflecting a 7-fold
difference in TCDD-binding affinity between the two species
(Fig. 2B). In addition, these experiments confirmed the reduced
[3H]TCDD-binding capacity of the tern AHR as compared to the
chicken AHR. Together, these analyses reveal that the in vitro-
expressed chicken and tern AHRs differ in three ways: the tern
AHR has a lower TCDD-binding affinity, a lower TCDD-
binding capacity, and its complex with TCDD is more easily
disrupted in the HAP assay.
In light of the substantial difference in the [3H]TCDD-binding
properties of the chicken and tern AHRs, we compared their
abilities to activate transcription of an AHRE-containing re-
porter gene in a transient transfection assay. COS-7 cells were
transfected with expression constructs for chicken, tern, or
mouse AHRs, an ARNT expression construct, and pGudLuc6.1.
All three AHRs increased the basal level of luciferase activity in
control cells in the absence of TCDD (Fig. 2C), as seen
previously for other AHRs (38–40). In cells transfected with
chicken or mouse AHR, TCDD induced luciferase activity in a
concentration-dependent manner. In contrast, the tern AHR did
not support TCDD-inducible transactivation of the luciferase
reporter gene, even at 10 nM TCDD, which produces maximal
activation of mouse and chicken AHRs (Fig. 2C). These results
show that the reduced activity inferred from assays with in
vitro-expressed tern AHR also is evident when this AHR is
expressed in a cellular context.
Chicken AHR LBD Confers High-Affinity TCDD-Binding to Tern AHR. To
determine the relative roles of the separate AHR functional
domains in the different properties of chicken and tern AHRs,
wemade six chimeric constructs by swapping the three functional
domains (DNA-bindingdimerization, ligand-binding, and
transactivation) of these AHRs (Fig. 3A). The chicken and tern
AHRs differ by 8, 3, and 52 aa, respectively, in these domains.
The chimeric and wild-type AHRs were expressed in vitro (Fig.
3B) and their ability to bind [3H]TCDD was measured by VS,
using a concentration of [3H]TCDD (2 nM) that would distin-
guish between the high-affinity and low-affinity binding forms of
avian AHRs (Fig. 2B). The three chimeric constructs containing
the chicken LBD exhibited substantial [3H]TCDD binding com-
parable to that of the wild-type chicken AHR (Fig. 3 C and D).
The remaining three chimeric AHRs, all of which possessed the
tern LBD, had very low [3H]TCDD binding, similar to that of the
wild-type tern AHR. Consistent with the in vitro [3H]TCDD
binding results, the chicken AHR and the three chimeric con-
structs with the chicken LBD supported TCDD-inducible lucif-
erase expression after transient transfection into COS-7 cells,
whereas the tern AHR and the other three chimeric constructs
did not (Fig. 3E). Thus, the LBD is responsible for the distinct
Fig. 3. Construction and functional analysis of chimeric AHRs. (A) Diagram of chimeric constructs. The DNA-binding domain (DBD), LBD, and transactivation
domain (TAD) of chicken and tern AHRs were used to generate all possible chimeric constructs. Numbers indicate amino acid differences between chicken and
tern AHRs. Abbreviations indicate source of domains from chicken (C) or tern (T) AHR. (B) IVTT of AHRs. AHRs were expressed by IVTT in the presence of
[35S]methionine. (C) Binding of [3H]TCDD to in vitro-expressed chimeric AHRs. AHR proteins were synthesized by IVTT, incubated with 2 nM [3H]TCDD for 18 h
at 4°C, and analyzed by VS. (D) Specific binding of [3H]TCDD to chimeric AHR proteins, calculated from fractions 10–20 of the curves in C. (E) Transactivation by
chicken, tern, and the chimeric AHR proteins. COS-7 cells were transfected with AHR constructs and treated with DMSO or TCDD (10 nM), and luciferase activities
were measured.
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functional properties of the chicken and tern AHRs both in vitro
and in whole cells.
Val-325 and Ala-381 in the Tern LBD Are Responsible for Altered
Ligand-Binding and Transactivation. The LBDs of chicken and tern
AHRs differ at three amino acid residues: Ala-257, Ile-324, and
Ser-380 in the chicken AHR are Thr-258, Val-325, and Ala-381
in the tern AHR. To assess the contribution of each of these
amino acids to the properties of the two AHRs, each of the
corresponding residues in the tern AHR was changed to its
chicken counterpart via site-directed mutagenesis (Fig. 4A). The
resulting tern AHR constructs (T258A, V325I, and A381S) were
expressed in vitro (Fig. 4B) and tested for [3H]TCDDbinding and
for their ability to transactivate the luciferase reporter gene. As
we saw earlier, the specific binding of [3H]TCDD to wild-type
tern AHR was 20% of that seen with the chicken AHR (Fig.
4 C and D). Specific binding of [3H]TCDD to the tern AHR
mutant T258A was low and similar to that of the wild-type tern
AHR. In contrast, tern AHR mutants V325I and A381S exhib-
ited levels of [3H]TCDD binding approaching those of the
wild-type chicken AHR (Fig. 4 C and D). Consistent with this,
the V325I and A381S mutants were able to activate luciferase
transcription in response to TCDD, whereas the T258A mutant
could not (Fig. 4E). Together, these results provide consistent
evidence that the reduced ability of the tern AHR to bind
[3H]TCDD and activate transcription is the result of the Val-325
and Ala-381 residues in its LBD.
Discussion
Vertebrate animals display a range of sensitivities to effects of
HAHs; aquatic birds, in particular, have greatly reduced sensi-
tivity as compared to typical laboratory models (20–24). We
show here that the reduced HAH sensitivity of common terns as
compared to chickens is associated with differences in functional
properties of the tern AHR, including lower TCDD-binding
affinity and binding capacity and reduced ability to activate
transcription in cell culture. We show also that this variation in
AHR function can be ascribed to two specific amino acid
differences within the LBD of this protein.
Structural and Functional Differences Between Chicken and Tern AHRs.
Chicken and tern AHRs share a high degree of sequence
conservation (see Supporting Text, which is published as sup-
porting information on the PNAS web site). Nevertheless, they
exhibit important functional differences. The difference in
TCDD-binding affinity between chicken and tern AHRs (7-fold)
is similar to that observed in previous studies of the mouse Ahrb
and Ahrd variants (11, 41) and in comparisons of the mouse Ahrb
and human AHR (34, 41, 42). The tern AHR and human AHR
share functional characteristics, including a reduced ligand-
binding affinity as well as lability of the AHR-TCDD complex
under in vitro conditions (37, 43).
The reduced ability of the tern AHR to bind [3H]TCDD and
activate transcription as compared to the chicken AHR is a result
of two amino acid differences. Independent V325I and A381S
substitutions in the tern AHR converted the ligand-binding and
transactivation abilities of the tern AHR to those of a chicken
AHR, strongly suggesting that both of these positions contribute
to the difference in function between chicken and tern AHRs.
Interestingly, Ala-381 in the tern AHR is homologous to (i.e., at
the equivalent position as) Ala-375 of the high-affinity mouse
Ahb1 protein and Val-375 and Val-380 of the lower-affinity
mouse Ahd and human AHR proteins, respectively (Fig. 8A,
which is published as supporting information on the PNAS web
Fig. 4. Construction and functional analysis of mutant tern AHRs. (A) Diagram of mutant tern AHRs. Each distinct amino acid in the LBD of the tern AHR was
changed to its chicken counterpart via site-directed mutagenesis (Thr258Ala, Val325Ile, and Ala381Ser). (B) Wild-type and mutant AHRs were expressed by IVTT
in the presence of [35S]methionine. (C) Binding of [3H]TCDD to in vitro-expressed mutant AHRs. AHR proteins were incubated with 2 nM [3H]TCDD and analyzed
by VS. (D) Specific binding of [3H]TCDD to mutant AHR proteins, calculated from results shown inC. (E) Transactivation by chicken, tern, and mutant AHR proteins.
COS-7 cells were transfected with AHR constructs and treated with DMSO or TCDD (10 nM), and luciferase activities were measured.















site, and Supporting Text). Previous studies have shown that this
residue is a key determinant of ligand binding in mammalian
AHRs (11, 41, 42, 44). Our results indicate that this position is
functionally important in diverse vertebrate AHRs. Although
the tern AHR possesses the residue (Ala) that is associated with
high-affinity binding in mammalian AHRs, the function of the
tern AHR is deficient in comparison to that of the chicken AHR,
which has a Ser in this position. This residue forms part of the
antiparallel -sheet in the ligand-binding pocket of the AHR, as
inferred from a recent AHR homology model (45, 46). Accord-
ing to this structural model, the reduction in binding affinity of
AHRs bearing Val at this position is the result of the larger
side-chain [Val (CH(CH3)2) as compared to Ala (CH3)], which
hinders access to the binding cavity (45). Our results show that
the presence of serine (CH3OH) in this position, as found in the
chicken AHR, appears to enhance the binding affinity andor
capacity, perhaps by stabilizing the ligand-receptor interaction
through hydrogen-bonding interactions with the dioxygen bridge
of TCDD. Regardless of the mechanism, the residues ValfAla
f Ser at this position appear to form a series of substitutions
leading to increasing stability of TCDD interaction with the
AHR.Whether a similar pattern of increased binding will be true
also for other AHR ligands remains to be determined.
Role of AHR in Differential Sensitivity to Dioxin-Like Compounds.The
difference in sensitivity to effects of HAHs between chickens
and terns has been demonstrated both in vivo and in cultured
cells (23, 24, 28). To what extent do the functional differences
shown here for these AHRs expressed in vitro explain the
species-specific in vivo sensitivity? Although in vitro assay sys-
tems such as reticulocyte lysate do not completely replicate the
normal cellular context in which these AHRs function, several
observations suggest that the functional differences measured in
vitro are likely to be relevant in vivo. (i) The reduced binding
affinity and capacity of the tern AHR in vitro are reflected in its
reduced ability to activate transcription in response to TCDD in
whole cells (Fig. 2C). (ii) Differences in ligand-binding affinity
among in vitro-expressed AHRs from mouse strains and humans
reflect in vivo differences (11, 16, 41, 47, 48). (iii) Two previous
studies (25, 26) using avian tissue cytosols showed differences in
AHR binding properties that correspond to differences in sen-
sitivity to HAHs. Although neither study involved terns, the
results are consistent with the idea that differences in AHR
binding properties among bird species occur within a native
tissue context. Thus, the functional differences in chicken and
tern AHRs demonstrated here in vitro are likely to contribute to
the differential in vivo sensitivity of these species.
Whether the 7-fold difference in binding affinity between
chicken and tern AHRs can fully explain the 80- to 250-fold
difference in species sensitivity is not clear. Because the biolog-
ical potency of AHR agonists is not a linear function of their
receptor-binding affinity (49), modest differences in affinity for
TCDD could result in larger differences in sensitivity in vivo, as
seen in mice expressing the human AHR (16) and in Xenopus
laevis (50). Alternatively, other factors such as differences in
AHR expression could be important determinants of in vivo
sensitivity, as suggested by studies in Ahr congenic mice (47),
mice hypomorphic at the Ahr locus (51), and transgenic mice
expressing the human AHR (16). Other properties of the AHR,
as well as other physiological or biochemical differences between
chickens and terns, also may contribute to the differential in vivo
sensitivity (see Supporting Text).
A lack of knowledge about species differences in sensitivity is
a major source of uncertainty in assessing the effects of HAHs
in humans and wildlife. A molecular understanding of the role
of the AHR in such differences will contribute to ecological and
human risk assessments by providing a mechanistic foundation
for extrapolation among species, facilitating predictions of those
species that may be most at risk. Sequencing and in vitro
functional analysis of AHRs or AHR LBDs could supplement
current approaches involving in vivo exposures (20, 24) or use of
cultured hepatocytes (21, 22) to assess species differences in
HAH sensitivity. Consistent with this, the AHR sequences of
other bird species that exhibit reduced sensitivity to HAHs show
amino acid differences like those of the tern AHR (Fig. 8B and
Supporting Text).
Materials and Methods
cDNA Cloning and Sequence Analysis. Hepatic RNA was isolated
from white leghorn chicken embryos and tern chicks, and initial
RT-PCR products were obtained as described (52). Chicken and
tern liver cDNAs were synthesized by using a Marathon cDNA
Amplification kit (Clontech). 5 and 3 RACE were performed
by using oligonucleotide primers (see Supporting Text) designed
to recognize both chicken and tern sequences, coupled with
adaptor primers. Gene-specific primers were B-31R and B-52R
for 5 RACE and B-21F and B-25F for 3 RACE. All PCR
products were cloned into the pGEM-T Easy vector (Promega)
and sequenced at the University of Maine Sequencing Facility
(Orono, ME).
Expression Constructs. Full-length chicken and tern AHR cDNAs
were amplified with primers Bkoz and Bterm. A Kozak consen-
sus sequence was incorporated into the 5 primer Bkoz. Several
clones were sequenced to ensure accuracy. Clones were digested
with SalI and XbaI at the primer sites and ligated into pcDNA
3.1Zeo() vector (Invitrogen) cut with XhoI and XbaI to
create pcDNA-GgAHR (chicken) and pcDNA-ShAHR (tern).
To construct the chimeric chickentern expression plasmids, six
fragments corresponding to the DNA-binding (chicken amino
acids 1–242, tern amino acids 1–243), ligand-binding (chicken
amino acids 243–390, tern amino acids 244–391), and transac-
tivation (chicken amino acids 391–858, tern amino acids 392–
859) domains were amplified by PCR using BkozNcoR, NcoF
NarR, and NarFBterm primers, respectively. NcoI and NarI
restriction sites were introduced via the primers, allowing liga-
tion of chicken and tern fragments to each other to create six
chimeric AHR cDNAs. These were ligated into the NotIXbaI
sites of the pcDNA 3.1Zeo() vector. Chimeric constructs
were verified by sequencing. Other expression constructs used
were: mouse AHR (pSPORTMAHR; C. Bradfield, University of
Wisconsin, Madison) (2), killifish ARNT2 (pcDNA-ARNT2)
(53), and pGudLuc6.1 (M. Denison, University of California,
Davis) (34).
Site-Directed Mutagenesis. We used a QuikChange XL site-
directed mutagenesis kit (Stratagene) to change three amino
acid residues in the tern LBD. The pcDNA-tern AHR construct
was the PCR template, and the primers were f258mt, r258mt,
f325mt, r325mt, f381mt, and r381mt. Mutated constructs were
sequenced completely.
In Vitro Protein Synthesis and Ligand-Binding Assay by Velocity
Sedimentation. TnT-Quick Coupled Reticulocyte Lysate Systems
(Promega) were used to synthesize [35S]methionine-labeled or
unlabeled proteins. [35S]Methionine-labeled IVTT reactions (5
l) were subjected to SDSPAGE, followed by fluorography.
[35S]-labeled proteins were quantified by scintillation counting of
excised gel fragments.
AHR ligand-binding was assessed by using unlabeled proteins
by VS on sucrose gradients in a vertical tube rotor as described
earlier (31, 32). IVTT reactions (50 l) were diluted 1:1 with
MEEDMG buffer (32) and incubated overnight at 4°C with
various concentrations of 2,3,7,8-tetrachloro[1,6-3H]dibenzo-p-
dioxin ([3H]TCDD; 35 Cimmol; Chemsyn Science Laborato-
ries, Lenexa, KS; 1 Ci  37 GBq). NSB was determined by
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parallel incubations of TnT lysate without AHR [unprogrammed
lysate (UPL)]; UPL lacks specific binding when assayed in the
presence and absence of excess 2,3,7,8-tetrachlorodibenzofuran
(32, 34).
Saturation Binding Analysis. Saturation binding was performed by
using two methods, which are outlined here and described in
detail in Supporting Text. The initial analyses used a modification
of an HAP adsorption assay (36). AHR proteins were synthe-
sized by IVTT, diluted in MEEDG buffer, and incubated with
[3H]TCDD for 22 h at 4°C. After the incubation, 200 l of
resuspended HAP was added to each tube, tubes were incubated
on ice, the HAP was washed, and radioactivity was measured. In
the second method, saturation binding was performed by using
VS on sucrose gradients (32) essentially as described above.
Saturation binding curves are plotted as ‘‘free’’ [3H]TCDD (nM)
vs. specifically bound [3H]TCDD after subtraction of NSB
(binding of [3H]TCDD to UPL) (34).
Cell Culture, Transfection, and Luciferase Assays. COS-7 cells were
from the American Type Culture Collection (Manassas, VA)
and maintained in DMEM (Sigma) with 10% FCS (Sigma) at
37°C under 5% CO2. Cells were plated at 3  104 cells per well
in 48-well plates. Transfections were carried out 24 h after
plating in triplicate wells. DNA and Lipofectamine 2000 reagent
(Life Technologies) were each diluted in serum-free DMEM.
For each well, a total of 300 ng of DNA was complexed with
1 l of Lipofectamine 2000. The mixture was then added to cells
in DMEM with serum. Cells were dosed 5 h after transfection
with either DMSO or TCDD (10 nM) at 0.5% final DMSO
concentration. Renilla luciferase (pRL-TK; Promega) was used
as the transfection control. Transfected DNA amounts were 5 ng
each of chicken or tern AHR construct, 50 ng of pSPORT-
MAHR (mouse AHR), 50 ng of pcDNA-ARNT2, 20 ng of
pGudLuc 6.1, and 3 ng of pRL-TK. The total amount of
transfectedDNAwas kept constant by addition of empty pcDNA
vector. Cells were lysed 18 h after dosing, and luminescence was
measured by using the Dual Luciferase Assay kit (Promega) in
a TD 2020 Luminometer (Turner Designs). Final luminescence
values are expressed as a ratio of the firefly luciferase units to the
Renilla luciferase units.
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